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There’s nothing more important than our health, but should we trust the Internet when we seek information
on medicines? In advance of a free public Polis seminar on social media and pharmaceuticals this Thursday
Katherine Relle describes her new research looking at what we can learn from what people say about medicines in
online forums.
Social media forums for healthcare contribute to the public
knowledge base and offer practical value.
When pharmaceutical companies engage in social media forums
to debate health issues, they must balance direct advertising
messages toward patients with their unique social responsibilities
for advancing medicine and public health.
The U.S. Food and Drug Administration (FDA) acknowledge that
these tensions exist for the pharmaceutical industry. In December
2011, the FDA published long-awaited draft guidelines for a social
media policy aimed at upholding a necessary degree of risk
communication for online advertising by the U.S. pharmaceutical industry.[1]
Social Media Policy
However, the FDA has been slow to issue formal regulations to provide an official social media policy, and a wooly
relationship exists between leading pharmaceutical players and the market capture of social media.[2] Benefits of
engaging in social media include enhancing reputation, customer service, and sales. Challenges include individual
or corporate lawsuits, cyber-security regulations, and, most extremely, public health crises. Therefore, a balance
must be struck for the pharmaceutical industry to appropriately harness online information. This is no easy task.
Original Research
My original research on Internet healthcare forums concludes that social media
forums are more than mere talking shops. They provide a valuable point of
reference for both patient-consumers and companies engaging in social media
listening.
A ten-variable content analysis which looked at a total of 600 posts across three
randomly selected online health-related forums, at 200 posts per forum, makes it
apparent that, with more industry involvement in social media, the negative
aspects of risk communication can be mitigated. The positive aspects of
personal profiling, education, and sentiment can be strengthened.
The following is a summary of data-related evidence from my research,
which allows me to make such conclusions:
First, nearly half (47 percent) of the online posts that were analysed involved risk messages. Online risk messaging
threatens company branding because informal social media messages may be inaccurate when not vetted by
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industry experts. Big pharma needs to engage with social media to protect company brands.
Second, even though patient-consumers were reluctant to provide much personal information (i.e., gender or age),
the information that was provided often elicited decipherable traits due to the nature of the posts. Personal
information in these posts provided interesting characteristics based on legitimate profiling assumptions, which
could help inform relevant marketing practices concerning which issues to convey and what tones to use in product
advertising.
Third, a quarter of the analysed posts explicitly sought information, and a majority of the posts engaged in an
informative dialogue about oral contraceptives. The educational nature of social media is apparent for the benefit of
product development.
Fourth, positive and negative sentiment about a wide range of oral contraceptive brands was varied. Increased
engagement in social media listening would allow companies to learn from these praises and dismissals,
associating brand names with sentiment analyses to examine best practices within the industry.
Finally, the current lack of regulatory guidance tilts the public sphere toward the consumer, but consumer
sovereignty is not necessarily the ideal.[3] When consumers fail to understand the complexity of science behind the
development of drugs, the industry’s advertising motives, or the politics involved with industry funding, dangerous
assumptions can be made. This negatively affects pharma and creates issues for public health.
Benefits of Engaging 
Big pharma should enter into the public sphere for the benefit of the industry and patient-consumers alike. The
benefits of engaging in the online public sphere seem to outweigh the risks, and suggestions for doing so are vast.
For example, if pharmaceutical companies wish to engage with social media, stakeholders could create their own
customized policies in a system of self-governance in lieu of widespread FDA regulations, so that individual
companies may advance within the industry. In doing so, a pharmaceutical social media ombudsman role might be
created in which registered physicians work impartially as appointed officers to police the communication between
pharma and the online public sphere of patient-consumers. This would require that impartial and trained physicians
be appointed to work within the industry as social media managers who proactively seek to rectify false information
about prescription drugs.
Innovation of this sort is crucial if more pharma companies choose to engage with social media forums. Such a
system of governance could also establish precedents for co-regulatory practices with the FDA. These steps will
define the future of the pharmaceutical industry. Further research conducted via interviews and focus groups will
contribute to the conclusions made in this research. For now, we can settle on the idea that the introduction of social
media into the corporate world is changing industry governance in unique ways and on a grand scale.
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